Intellia completes enrollment in MAGNITUDE-2 Phase 3 trial of Nex-z in ATTRv-PN; cash $614.8M, runway into 2028

Intellia Therapeutics completed enrollment in the MAGNITUDE-2 Phase 3 trial of Nex-z in ATTRv-PN. It reported cash of $614.8 million and expects a runway at least into 2028.

Detected & updated continuously · Source: Nebula